OncLive TV

Amy L. Cummings, MD, discusses the significance of the phase 3 FLAURA trial evaluating osimertinib in locally advanced or metastatic non–small cell lung cancer (NSCLC).

Amandeep Godara, MBBS, discusses CAR T-cell therapies currently available for patients with multiple myeloma.

Eunice Wang, MD, discusses treatment options in unfit patients with acute myeloid leukemia.

Yvonne Chao, MD, PhD, discusses key trials leading to FDA approvals in metastatic non–small cell lung cancer.

Ruth M. O’Regan, MD, discusses how results from the phase 2 RIGHT Choice trial could influence the treatment paradigm in hormone receptor–positive, HER2-negative breast cancer.

Timothy Burns, MD, PhD, discusses the evolving use of antibody-drug conjugates in HER2-mutant non–small cell lung cancer.

Sapna Patel, BA, MD, discusses the rationale for evaluating the use of pembrolizumab before and after surgery for patients with advanced melanoma.

Brian Henick, MD, discusses the importance of further exploring biomarkers in the immune microenvironment for immunotherapy in patients with lung cancer.

R. Lor Randall, MD, FACS, discusses, the importance of correctly diagnosing mesenchymal chondrosarcoma.

Edward B. Garon, MD, MS, discusses the use of PD-L1 inhibitor and CTLA-4 inhibitor combinations in non–small cell lung cancer.

Matthew Brunner, MD, discusses how the phase 2 BMT CTN 1902 trial of anti-BCMA CAR T-cell therapy will attempt to address an area of unmet need in multiple myeloma.

Martin Edelman, MD, and Linda Fleisher, PhD, MPH, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

David Gerber, MD, and Chika Nwachukwu, MD, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Anthony B. El-Khoueiry, MD, and Chanita Hughes-Halbert, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Brian Mitzman, MD, FACS, FCCP, discusses findings from the phase 3 CheckMate 816 trial in patients with resectable non–small cell lung cancer.

Matthew Brunner, MD, discusses how to best approach the navigation of advanced imaging modalities in relapsed/refractory multiple myeloma.

Akash Mukherjee, MD, discusses the use of post-transplant maintenance rituximab in patients with mantle cell lymphoma who have received autologous stem cell transplant and considerations for using bendamustine/rituximab or BR plus cytarabine in elderly patients who are unfit for transplant.

Jubilee Brown, MD, professor, director, gynecologic oncology, Levine Cancer Institute, Atrium Health, discusses benefits associated with PARP inhibitor maintenance therapy in the upfront and recurrent settings of ovarian cancer.

Jean Wright, MD, discusses the benefit of moderate hypofractionation in patients for adjuvant radiotherapy in patients with early-stage breast cancer.

Steven Cai, MD, FACS, discusses the ongoing effort to address disparities in breast cancer care, and the importance of improving access to care for underserved patients.

Hyman B. Muss, MD, discusses the use of metronomic chemotherapy in metastatic breast cancer.

Christos Fountzilas, MD, FACP, discusses findings from a study of molecular characterization in patients with colorectal cancer treated with cetuximab, an EGFR inhibitor, and pembrolizumab, a PD-1 inhibitor.

Evan Y. Yu, MD, discusses new data and continuing conversations regarding the use of PARP inhibitors and targeted radioligand therapies in prostate cancer.

Michael A. Carducci, MD, discusses the significance of two ongoing clinical trials in prostate cancer: the phase 3 CAPItello-280 trial (NCT05348577) and phase 3 INDICATE study (EA8191; NCT04423211).

Zachary Epstein-Peterson, MD, discusses important updates in mantle cell lymphoma treatment, including the safety and feasibility of disease observation in patients with indolent MCL and the treatment of patients with TP53-mutated MCL.

Michael S. Cookson, MD, MMHC, discusses how understanding the relationship between key predictive factors and disease progression can help better inform the overall management of prostate cancer.

Adam D. Cohen, MD, discusses the current landscape of treatment options in multiple myeloma, and elaborates on attempts to utilize these options in earlier lines of therapy.

Edgardo S. Santos, MD, FACP, discusses the current treatment landscape for patients with squamous cell carcinoma of the lung.

Tycel Phillips, MD, MPH, discusses how to approach selecting BTK inhibitors for patients with mantle cell lymphoma and treatment decisions following disease progression on a BTK inhibitor.

Priyanka Sharma, MD, discusses updates in optimal systemic therapy strategies in early-stage triple-negative breast cancer.